Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyper-CVAD Plus Rituximab for Untreated Mantle Cell Lymphoma
NCT00581854Phase 2Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- Jun 2000
- Primary completion
- Jun 2006
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in mantle cell lymphoma (MCL), sponsored by University of Wisconsin–Madison. Primary endpoint: Complete Response Rate to Induction Therapy at 37 months. Started Jun 2000; status: completed.
02
Drugs
rituximab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00581854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00581854.